New Research Reports

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Weak start for FY26 likely. Salary hike postponed due to uncertainty in the demand environment

Tata Steel (TSL) has embarked on a major transformation plan at Tata Steel Netherlands (TSN) – built on a multi-pronged approach to maximise production efficiencies, lower fixed costs, optimise product mix and margins.

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.

TCS Q4FY25 reported revneue stood at $7,465 million, down 1% q-o-q/up 1.4% y-o-y, missing our estimate of $7,501 million. Revenue growth in constant currency (CC) terms stood at 2.5% y-o-y. Revenue in rupee terms stood at Rs. 64,479 crore, up 0.8% q-o-q/5.3% y-o-y.

Tata Steel Nederland (TSN) has adopted a comprehensive transformation program to maximize production efficiencies, reduce fixed costs, and optimize product mix and margins.

India aluminum consumption is expected to double to 11.37mt, while copper consumption is likely to grow 2.5x to 2.54mt over the next decade. Hindalco Industries (HNDL), at its annual investors' day, outlined its long-term strategy for both India business and Novelis. Out of already announced USD5bn India capex, HNDL is investing ~USD2bn and USD1.6bn in upstream businesses of aluminum and copper, respectively, while the rest would be spent on various downstream projects and coal mining. With captive coal mines...

We attended Hindalco Industries’ (HNDL) Investor Day. Long-term capacity growth aspirations in India, focus on value-added products dovetailing with domestic requirements.

We recently attended Hindalco’s Investor Day 2025 where management unveiled ~$10bn expansion plan for Novelis and India, along with multiple strategic initiatives, which would help strengthen its market leadership.

We maintain our BUY rating on the stock